KSKoen Schruers

Koen Schruers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koen Schruers has a total of 252 co-authors. Here are the top co-authors by number of shared publications:

  • Liesbet Goossens

    Department of Psychiatry and Neuropsychology School for Mental Health and Neuroscience, Maastricht University Maastricht Netherlands

    8 shared publications
  • Therese van Amelsvoort

    Department of Psychiatry and Psychology, MUMC+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands

    6 shared publications
  • Stijn Michielse

    Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands

    5 shared publications
  • Iris Lange

    Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands

    4 shared publications
  • Nicole K. Leibold

    Department of Psychiatry & Neuropsychology, Mental Health and Neuroscience Research Institute (MHeNs), Faculty of Health, Medicine and Life Sciences, Maastricht University, P.O. Box 616, Maastricht 6200 MD, the Netherlands

    4 shared publications
  • Ulrich Reininghaus

    Department of Public Mental Health, Central Institute of Mental Health, Medical Faculty Mannheim Heidelberg University Mannheim Germany

    4 shared publications

Latest Publications

  • Open Access

    Transcranial Magnetic Stimulation for Patients with Exposure Therapy Resistant Obsessive-Compulsive Disorder (TETRO): Study Protocol for a Multicenter Randomized Controlled Trial

    by Tjardo S Postma, Ysbrand D van der Werf, Martijn Arns, Neeltje M Batelaan, Manou van Den Berg, Judith E Bosmans, Merijn Eikelenboom, Gert-Jan Hendriks, Adriaan W Hoogendoorn, Mirjam Kampman, et al.

    Background: Obsessive-compulsive disorder (OCD) is a disabling mental disorder, characterized by obsessions, compulsions, and substantial morbidity. Approximately 50% of adults with OCD fail to achieve satisfactory outcomes from first-line treatments, such as exposure therapy with response prevention (ERP), with or without medication. This leads to chronic social, educational, and occupational impairment. While invasive procedures such as deep brain stimulation are available for severe, treatment-refractory cases, a need remains for less invasive alternatives. Repetitive transcranial magnetic stimulation (rTMS), a noninvasive intervention, shows promise in reducing OCD symptoms. Unlike in depression, rTMS is not yet reimbursed for OCD in the Dutch healthcare system. Objective: This study examines the efficacy and cost-effectiveness of low-frequency (1Hz) rTMS targeting the presupplementary motor area (pre-SMA) compared to sham rTMS as an adjuvant treatment to ERP in adults with OCD with inadequate response to first-line treatment. Methods: A total of 250 adults with OCD will be enrolled in this multicenter randomized controlled trial. Participants will be randomly assigned to ERP combined with either active or sham 1Hz rTMS over the pre-SMA. Treatment is administered 4 times weekly for at least 5 weeks (20 rTMS-ERP sessions), with optional extension of 1 to 2 weeks, up to 28 rTMS-ERP sessions. Clinical assessments occur at baseline, weekly during treatment, posttreatment, and at 3, 6, and 12 months follow-up. Participants undergo pre- and posttreatment (functional) (MRI) scans, including a symptom provocation task. Blood sampling takes place pre- and posttreatment and at 3-month follow-up. The primary outcome is OCD severity at posttreatment, as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Secondary outcomes include functional improvement, quality of life, and societal costs. Pretreatment symptom profiles, genotype, and brain network topology will be analyzed as predictors of response and relapse risk. Pre-to-post treatment change in blood-based and magnetic resonance (MR)-based neuroplasticity markers will help explore differential mechanisms between ERP alone and combined rTMS-ERP. We expect that the verum rTMS protocol will be cost-effective compared to sham-rTMS. Results: Recruitment started in April 2022, and as of February 2026, 201 participants have been enrolled. Posttreatment assessments are projected to be completed in December 2026, with final one-year follow-up evaluations anticipated by the end of 2027. Conclusions: To our knowledge, this study is the first adequately powered randomized controlled trial examining efficacy, cost-effectiveness, and mechanism of action of rTMS for OCD as adjuvant therapy to ERP. In case of efficacy and/or cost-effectiveness, it will pave the way for rTMS as insured health care for adults with OCD in the Netherlands, and possibly other European countries. Furthermore, this trial will provide insight into the mechanisms of treatment response to intensive ERP, with and without adjunctive rTMS, as well as potential side effects, individual variability, and long-term outcomes in adults with OCD.

  • Open Access

    Barriers and facilitators to implementing deep brain stimulation for psychiatric disorders: a systematic review

    by Dominika M. Karaszewska, Eva M. K. Beunk, Gosse J. J. Mol, Martijn Beudel, Albert F. G. Leentjens, Koen Schruers, Rick Schuurman, Pepijn van Den Munckhof, Damiaan Denys, Roel J. T. Mocking

    Background Deep brain stimulation (DBS) is effective in treating severe obsessive-compulsive disorder (OCD) and treatment-resistant depression (TRD). However, patient referrals for DBS remain lower than expected based on prevalence and eligibility. Understanding the factors behind this gap is crucial for improving DBS implementation. This study aimed to identify key barriers and facilitators influencing DBS use for OCD and TRD. Insights from this research may help policymakers and clinicians address challenges, ultimately enhancing DBS accessibility and effectiveness for psychiatric disorders. Methods A systematic review was performed using four electronic databases until May 1st 2024 following PRISMA and ENTREQ guidelines. Eligible for inclusion were quantitative and qualitative studies describing facilitators or barriers for implementing DBS in psychiatry. Results We included 28 studies, out of which 11 in TRD, 5 in OCD and 12 in both, and revealed a spectrum of barriers, including ethical concerns, safety issues, stigma and knowledge gaps. Promising facilitators include educational initiatives, specialized psychiatric DBS care and stakeholder engagement. Discussion This first systematic review provides a comprehensive overview of barriers and facilitators affecting DBS implementation for OCD and TRD. Key areas include establishing consensus on treatment resistance, refining referral guidelines, addressing knowledge gaps among clinicians—such as psychiatrists unfamiliar with neurosurgical psychiatric treatments—and improving DBS’s media image to reduce stigma. Limitations include a large portion of included articles from the same contributors and a predominance of US-based studies, potentially affecting generalizability of findings. International perspectives should be included in future studies to ensure a more widely applicable understanding of DBS implementation challenges.

  • Open Access

    Longitudinal outcomes and clinical predictors of VC/VS deep brain stimulation in severe obsessive–compulsive disorder: A case series

    by Tatyana Branco Nunes, Liesbet Goossens, Yasin Temel, Anne E.P. Mulders, David E.J. Linden, Ersoy Kocabiçak, Albert F.G. Leentjens, Sonja A. Kotz, Koen R.J. Schruers, Linda Ackermans

  • Open Access

    Absence of a meaningful effect of intranasal oxytocin on trusting behavior: a registered report with pooled equivalence testing

    by Charlotte F. Kroll, Koen R.J. Schruers, Wolfgang Viechtbauer, Claudia Vingerhoets, Leonie Seidel, Arno Riedl, Dennis Hernaus


  • Open Access

    Variation in DNA methylation of the oxytocin gene is associated with prosocial, reward-related, decision-making

    by Charlotte F. Kroll, Nicole K. Leibold, Claudia Vingerhoets, Gunter Kenis, Daniel L.A. van Den Hove, Arno Riedl, Koen R.J. Schruers, Dennis Hernaus

  • Open Access

    Transcranial magnetic stimulation for patients with exposure therapy resistant obsessive-compulsive disorder: TETRO - a study protocol for a multicenter randomized controlled trial (Preprint)

    by Tjardo Schato Postma, Ysbrand D van der Werf, Martijn Arns, Neeltje M Batelaan, Manou van Den Berg, Judith E Bosmans, Merijn Eikelenboom, Gert-Jan Hendriks, Adriaan W Hoogendoorn, Mirjam Kampman, et al.

    BACKGROUND Obsessive-compulsive disorder (OCD) is a disabling mental disorder, characterized by obsessions, compulsions and substantial morbidity. Approximately 50% of adults with OCD fail to achieve satisfactory outcomes from first-line treatments such as exposure therapy with response prevention (ERP) with or without medication. This leads to chronic social, educational, and occupational impairment. While invasive procedures such as deep brain stimulation are available for severe, treatment-refractory cases, a need remains for less invasive alternatives. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive intervention, shows promise in reducing OCD symptoms. Unlike in depression, rTMS is not yet reimbursed for OCD in the Dutch healthcare system. OBJECTIVE This study examines the efficacy and cost-effectiveness of low-frequency (1Hz) rTMS targeting the pre-supplementary motor area (pre-SMA) compared to sham rTMS as an adjuvant treatment to ERP in adults with OCD with inadequate response to first-line treatment. METHODS 250 adults with OCD will be enrolled in this multicenter randomized controlled trial. Participants will be randomly assigned to ERP combined with either active or sham 1Hz rTMS over the pre-SMA. Treatment is administered four times weekly for at least five weeks (20 rTMS-ERP sessions), with optional extension of one to two weeks, up to 28 rTMS-ERP sessions. Clinical assessments occur at baseline, weekly during treatment, post-treatment, and at 3, 6, and 12 months follow-up. Participants undergo pre- and post-treatment (functional) MRI scans, including a symptom provocation task. Blood sampling takes place pre- and post-treatment and at 3 months follow-up. The primary outcome is OCD severity at post-treatment, as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Secondary outcomes include functional improvement, quality of life and societal costs. Pre-treatment symptom profiles, genotype, and brain network topology will be analyzed as predictors of response and relapse risk. Pre-to-post treatment change in blood-based and MR-based neuroplasticity markers will help explore differential mechanisms between ERP alone and combined rTMS-ERP. We expect that the verum rTMS protocol will be (cost-)effective compared to sham-rTMS. RESULTS Recruitment started in April 2022, and as of February 2026, 201 participants have been enrolled. Post-treatment assessments are projected to be completed in December 2026 with final one-year follow-up evaluations anticipated by the end of 2027. CONCLUSIONS To our knowledge, this study is the first adequately-powered randomized controlled trial examining efficacy, cost-effectiveness and mechanism of action of rTMS for OCD as adjuvant therapy to ERP. In case of efficacy and/or cost-effectiveness, it will pave the way for rTMS as insured health care for adults with OCD in the Netherlands, and possibly other European countries. Furthermore, this trial will provide insight into the mechanisms of treatment response to intensive ERP, with and without adjunctive rTMS, as well as potential side effects, individual variability, and long-term outcomes in adults with OCD. CLINICALTRIAL This trial is registered at clinicaltrials.gov with code: NCT05331937, last updated on January 15th 2026.

  • Open Access

    Boosting memory activation to target aversive memories in dual-task interventions

    by Mae D. Nuijs, Tjeu P. M. Theunissen, Kevin van Schie, Thomas C. Brouwers, Klara de Cort, Koen R. J. Schruers, Suzy J. M. A. Matthijssen

    Background and Objectives: During a standard dual-task intervention, an individual recalls a memory while performing a dual-task. It is yet unclear to which extent a memory needs to be activated during a dual-task intervention to be most effective for memory desensitization. We investigated whether boosting memory activation by adding a visual retrieval cue during a dual-task intervention could enhance the desensitization of aversive memories.Methods: An aversive memory was induced using a trauma film. Then, participants (N = 136) were randomly assigned to either (1) Recall + Working Memory (WM) Task + Screenshot, (2) Recall + WM Task, (3) Recall Only, or (4) WM Task Only condition. Memory vividness and distress were assessed prior and after the intervention, and at 1-week follow-up.Results: Overall, the evidence suggested that adding a visual retrieval cue of an aversive memory to a standard dual-task intervention did not lead to greater reductions in memory vividness and distress compared to a standard dual-task intervention without a cue. Exploratory analyses revealed that there was strong evidence for an alternative hypothesis: All conditions involving WM taxation were equally effective in reducing memory distress and vividness, irrespective of recall instructions or reactivation cues, and outperformed the Recall Only condition.Limitations: Participants did not think more of the trauma film when provided with a visual retrieval cue during the standard dual-task intervention compared to not seeing such a cue. Hence, it is possible that the visual retrieval cue was not processed sufficiently to boost memory activation.Conclusions: Adding a visual retrieval cue to a dual-task intervention did not enhance memory desensitization in this study with non-clinical participants. Instead, based on the exploratory analyses, the data more likely suggest that (continuous) reactivation of aversive memories during a dual-task intervention may not be necessary for effective memory desensitization.


  • Open Access

    High Doses of Antidepressants and Long-term Treatment of Obsessive-compulsive Disorder: Another Barrier to Accessing Deep Brain Stimulation?

    by Emma Verstraete, Erwin Dreesen, Koen Schruers, Franciska Am Desplenter, Chris Bervoets


  • Open Access

    Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression

    by Abel (K.A.J.) Busz, Emma (E.J.) Schmidt, Rob (R.H.S.) van Den Brink, Karen (K.) Foeken, Marasha (M.) de Jong, Joost (J.B.C.) Mertens, Martijn (M.S.) van Noorden, Etienne (E.J.F.L.) Olivier, Koen (K.R.J.) Schruers, Sara (S.I.J.) Schutters, et al.

  • Open Access

    Feasibility of eye movement desensitization and reprocessing in a person with dementia and post-traumatic stress disorder: A case report

    by J.E. Ruisch, M. van Kordenoordt, C. Steins, M.A.M.J. Daamen, K.R.J. Schruers, S. Sobczak, E.M.J. Gielkens